Full Text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

European Pharmacopoeia monograph 2371 describes the production of homeopathic preparations. A specific efficacy of these preparations in high dilution levels is questionable in view of basic scientific principles. There is empirical evidence for such effects, for example in a Lemna-intoxication bioassay published 2010. To test the replicability and robustness of this bioassay, we conducted two experimental series (five independent blinded and randomised experiments each). The specimen of Lemna gibba L., clone-number 9352, were stressed in arsenic solution for 48 h (158 mg/L AsNa2HO4 (250 mg/L in series 2)), then grew in either As2O3 preparations produced according to Eu. Pharm. Monogr. 2371 or control solution. Comparing the area-related relative growth rate of day 3–9 (rgr 3–9) between treatment and control groups for each series showed differences that were not significant in series 1 (p = 0.10), significant in series 2 (p = 0.04) and significant in the pooled data of both series (p < 0.01). The effect direction (rgr 3–9 increase) was comparable to experiments of 2010, but the effect size was smaller, likely due to a changed light cycle. These results are not compatible with the hypothesis that the application of European Pharmacopoeia monograph 2371 results in pharmaceutical preparations without specific effects. Further studies are needed to investigate a potential mode of action explaining these effects.

Details

Title
Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371
Author
Ücker, Annekathrin 1 ; Baumgartner, Stephan 2 ; Martin, David 3   VIAFID ORCID Logo  ; Jäger, Tim 4 

 Institute of Integrative Medicine, University of Witten/Herdecke, 58455 Witten, Germany; [email protected] (S.B.); [email protected] (D.M.); [email protected] (T.J.); Center for Complementary Medicine, Institute for Infection Prevention and Hospital Epidemiology, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany 
 Institute of Integrative Medicine, University of Witten/Herdecke, 58455 Witten, Germany; [email protected] (S.B.); [email protected] (D.M.); [email protected] (T.J.); Institute of Complementary and Integrative Medicine, University of Bern, 3012 Bern, Switzerland; Society for Cancer Research, 4144 Arlesheim, Switzerland 
 Institute of Integrative Medicine, University of Witten/Herdecke, 58455 Witten, Germany; [email protected] (S.B.); [email protected] (D.M.); [email protected] (T.J.) 
 Institute of Integrative Medicine, University of Witten/Herdecke, 58455 Witten, Germany; [email protected] (S.B.); [email protected] (D.M.); [email protected] (T.J.); Center for Complementary Medicine, Institute for Infection Prevention and Hospital Epidemiology, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; Institute of Complementary and Integrative Medicine, University of Bern, 3012 Bern, Switzerland 
First page
552
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22279059
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2642347328
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.